Literature DB >> 33802255

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis.

Angelo Ruggiero1, Gabriella Fabbrocini1, Sara Cacciapuoti1, Eleonora Cinelli1, Lucia Gallo1, Matteo Megna1.   

Abstract

Psoriasis is an immune-mediated, chronic inflammatory disease, which mainly affects the skin, although it has systemic pathological effects. Comorbidities of psoriasis include ocular disorders, which are often nonspecific or mildly symptomatic. The aim of this study was to show the importance of ocular-disease screening in psoriatic patients using the Ocular Manifestations in Psoriasis Screening (OcMaPS) questionnaire. Patients suffering from moderate-to-severe psoriasis referring at our outpatient-clinic were consecutively enrolled. Each patient was asked to complete a screening questionnaire (OcMaPS). Patients reporting ocular symptoms were referred for an ophthalmological examination. A total of 372 patients were enrolled in the study. Ocular symptoms were detected in 39 patients (10.5%), and 37 patients were referred to ophthalmological examination which confirmed the presence of ocular manifestation in 30 patients. There were three cases (10%) of uveitis, 14 (46.6%) of dry eye and 13 (43.3%) of cataract, in progress or already treated with surgery. In the remaining seven patients, no ocular manifestations were found. Ocular manifestations in psoriatic patients are not rare. It is important to be aware of ocular symptoms in psoriatic patients, screening patients (with a consultation or OcMaPS questionnaire), which leads to earlier diagnosis and treatment.

Entities:  

Keywords:  ocular involvement in psoriasis; ocular psoriasis; psoriasis comorbidity; screening questionnaire

Year:  2021        PMID: 33802255      PMCID: PMC7958956          DOI: 10.3390/jcm10051031

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  6 in total

Review 1.  Identifying and Treating Ocular Manifestations in Psoriasis.

Authors:  Mahsaw Motlagh; Christopher Fortenbach; Howard I Maibach; Bobeck S Modjtahedi
Journal:  Am J Clin Dermatol       Date:  2021-11-03       Impact factor: 7.403

2.  Evaluation of ocular surface epithelial and stromal thicknesses in psoriasis using anterior segment optical coherence tomography.

Authors:  Ismail Ersan; Sevilay Kilic; Selda Işik
Journal:  Int Ophthalmol       Date:  2022-04-07       Impact factor: 2.029

Review 3.  Comorbidity in Adult Psoriasis: Considerations for the Clinician.

Authors:  Christine Daugaard; Lars Iversen; Kasper Fjellhaugen Hjuler
Journal:  Psoriasis (Auckl)       Date:  2022-06-10

Review 4.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

5.  Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.

Authors:  Matteo Megna; Luca Potestio; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Psoriasis (Auckl)       Date:  2022-07-14

6.  The Potential Role of Serum Tau Protein (MAPT), Neuronal Cell Adhesion Molecule (NrCAM) and Neprilysin (NEP) in Neurodegenerative Disorders Development in Psoriasis-Preliminary Results.

Authors:  Anna Baran; Julia Nowowiejska; Justyna Magdalena Hermanowicz; Beata Sieklucka; Julita Anna Krahel; Paulina Kiluk; Dariusz Pawlak; Iwona Flisiak
Journal:  J Clin Med       Date:  2022-08-27       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.